Dual mechanism for inhibition of inwardly rectifying Kir2.x shannels by quinidine involving direct pore block and PIP2-interference

Class IA antiarrhythmic drug quinidine was one of the first clinically used compounds to terminate atrial fibrillation and acts as multichannel inhibitor with well-documented inhibitory effects on several cardiac potassium channels. In the mammalian heart, heteromeric assembly of Kir2.1-2.3 channels...

Full description

Saved in:
Bibliographic Details
Main Authors: Köpple, Christoph (Author) , Scherer, Daniel (Author) , Seyler, Claudia (Author) , Scholz, Eberhard P. (Author) , Thomas, Dierk (Author) , Katus, Hugo (Author) , Zitron, Edgar (Author)
Format: Article (Journal)
Language:English
Published: 1 May 2017
In: The journal of pharmacology and experimental therapeutics
Year: 2017, Volume: 361, Issue: 2, Pages: 209-218
ISSN:1521-0103
DOI:10.1124/jpet.116.238287
Online Access:Verlag, Volltext: http://dx.doi.org/10.1124/jpet.116.238287
Verlag, Volltext: http://jpet.aspetjournals.org/content/361/2/209
Get full text
Author Notes:Christoph Koepple, Daniel Scherer, Claudia Seyler, Eberhard Scholz, Dierk Thomas, Hugo A. Katus, and Edgar Zitron

MARC

LEADER 00000caa a2200000 c 4500
001 1582522308
003 DE-627
005 20230427193234.0
007 cr uuu---uuuuu
008 181102s2017 xx |||||o 00| ||eng c
024 7 |a 10.1124/jpet.116.238287  |2 doi 
035 |a (DE-627)1582522308 
035 |a (DE-576)512522308 
035 |a (DE-599)BSZ512522308 
035 |a (OCoLC)1341021999 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Köpple, Christoph  |d 1984-  |e VerfasserIn  |0 (DE-588)1077667922  |0 (DE-627)837385067  |0 (DE-576)446609935  |4 aut 
245 1 0 |a Dual mechanism for inhibition of inwardly rectifying Kir2.x shannels by quinidine involving direct pore block and PIP2-interference  |c Christoph Koepple, Daniel Scherer, Claudia Seyler, Eberhard Scholz, Dierk Thomas, Hugo A. Katus, and Edgar Zitron 
264 1 |c 1 May 2017 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Im Titel ist die Zahl "2" nach PIP tiefgestellt 
500 |a Gesehen am 02.11.2018 
520 |a Class IA antiarrhythmic drug quinidine was one of the first clinically used compounds to terminate atrial fibrillation and acts as multichannel inhibitor with well-documented inhibitory effects on several cardiac potassium channels. In the mammalian heart, heteromeric assembly of Kir2.1-2.3 channels underlies IK1 current. Although a low-affinity block of quinidine on Kir2.1 has already been described, a comparative analysis of effects on other Kir2.x channels has not been performed to date. Therefore, we analyzed the effects of quinidine on wild-type and mutant Kir2.x channels in the Xenopus oocyte expression system. Quinidine exerted differential inhibitory effects on Kir2.x channels with the highest affinity toward Kir2.3 subunits. Onset of block was slow and solely reversible in Kir2.2 subunits. Quinidine inhibited Kir2.x currents in a voltage-independent manner. By means of comparative Ala-scanning mutagenesis, we further found that residues E224, F254, D259, and E299 are essential for quinidine block in Kir2.1 subunits. Analogously, quinidine mediated Kir2.3 inhibition by binding corresponding residues E216, D247, D251, and E291. In contrast, Kir2.2 current block merely involved corresponding residue D260. Using channel mutants with altered (phosphatidylinositol 4,5-bisphosphate PIP2) affinities, we were able to demonstrate that high PIP2 affinities (i.e., Kir2.3 I214L) correlate with low quinidine sensitivity. Inversely, mutant channels interacting only weakly with PIP2 (i.e., Kir2.1 K182Q, and L221I) are prone to a higher inhibitory effect. Thus, we conclude that inhibition of Kir2.x channels by quinidine is mediated by joint modes of action involving direct cytoplasmic pore block and an impaired channel stabilization via interference with PIP2. 
700 1 |a Scherer, Daniel  |d 1980-  |e VerfasserIn  |0 (DE-588)1014627524  |0 (DE-627)705275191  |0 (DE-576)348200811  |4 aut 
700 1 |a Seyler, Claudia  |d 1976-  |e VerfasserIn  |0 (DE-588)13306476X  |0 (DE-627)533316871  |0 (DE-576)299599523  |4 aut 
700 1 |a Scholz, Eberhard P.  |d 1978-  |e VerfasserIn  |0 (DE-588)13163660X  |0 (DE-627)512033994  |0 (DE-576)298640589  |4 aut 
700 1 |a Thomas, Dierk  |d 1974-  |e VerfasserIn  |0 (DE-588)123896258  |0 (DE-627)706465601  |0 (DE-576)29393164X  |4 aut 
700 1 |a Katus, Hugo  |d 1951-  |e VerfasserIn  |0 (DE-588)108916618  |0 (DE-627)577155040  |0 (DE-576)289625076  |4 aut 
700 1 |a Zitron, Edgar  |d 1977-  |e VerfasserIn  |0 (DE-588)130512966  |0 (DE-627)503032549  |0 (DE-576)298241196  |4 aut 
773 0 8 |i Enthalten in  |t The journal of pharmacology and experimental therapeutics  |d Bethesda, Md. : ASPET, 1909  |g 361(2017), 2, Seite 209-218  |h Online-Ressource  |w (DE-627)269534636  |w (DE-600)1475023-5  |w (DE-576)077884736  |x 1521-0103  |7 nnas  |a Dual mechanism for inhibition of inwardly rectifying Kir2.x shannels by quinidine involving direct pore block and PIP2-interference 
773 1 8 |g volume:361  |g year:2017  |g number:2  |g pages:209-218  |g extent:10  |a Dual mechanism for inhibition of inwardly rectifying Kir2.x shannels by quinidine involving direct pore block and PIP2-interference 
856 4 0 |u http://dx.doi.org/10.1124/jpet.116.238287  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://jpet.aspetjournals.org/content/361/2/209  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181102 
993 |a Article 
994 |a 2017 
998 |g 130512966  |a Zitron, Edgar  |m 130512966:Zitron, Edgar  |d 910000  |d 910100  |e 910000PZ130512966  |e 910100PZ130512966  |k 0/910000/  |k 1/910000/910100/  |p 7  |y j 
998 |g 108916618  |a Katus, Hugo  |m 108916618:Katus, Hugo  |d 910000  |d 910100  |e 910000PK108916618  |e 910100PK108916618  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 123896258  |a Thomas, Dierk  |m 123896258:Thomas, Dierk  |d 910000  |d 910100  |e 910000PT123896258  |e 910100PT123896258  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 13163660X  |a Scholz, Eberhard P.  |m 13163660X:Scholz, Eberhard P.  |d 910000  |d 910100  |e 910000PS13163660X  |e 910100PS13163660X  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 13306476X  |a Seyler, Claudia  |m 13306476X:Seyler, Claudia  |d 910000  |d 910100  |e 910000PS13306476X  |e 910100PS13306476X  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 1014627524  |a Scherer, Daniel  |m 1014627524:Scherer, Daniel  |d 910000  |d 910100  |e 910000PS1014627524  |e 910100PS1014627524  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1077667922  |a Köpple, Christoph  |m 1077667922:Köpple, Christoph  |d 910000  |d 910100  |e 910000PK1077667922  |e 910100PK1077667922  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1582522308  |e 303022404X 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Dual mechanism for inhibition of inwardly rectifying Kir2.x shannels by quinidine involving direct pore block and PIP2-interference","title":"Dual mechanism for inhibition of inwardly rectifying Kir2.x shannels by quinidine involving direct pore block and PIP2-interference"}],"id":{"doi":["10.1124/jpet.116.238287"],"eki":["1582522308"]},"physDesc":[{"extent":"10 S."}],"relHost":[{"part":{"volume":"361","year":"2017","pages":"209-218","extent":"10","issue":"2","text":"361(2017), 2, Seite 209-218"},"language":["eng"],"note":["Gesehen am 06.02.25","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1909/10 -"],"disp":"Dual mechanism for inhibition of inwardly rectifying Kir2.x shannels by quinidine involving direct pore block and PIP2-interferenceThe journal of pharmacology and experimental therapeutics","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"JPET online"}],"recId":"269534636","id":{"zdb":["1475023-5"],"issn":["1521-0103"],"eki":["269534636"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"a publication of the American Society for Pharmacology and Experimental Therapeutics","title":"The journal of pharmacology and experimental therapeutics","title_sort":"journal of pharmacology and experimental therapeutics"}],"origin":[{"dateIssuedKey":"1909","publisherPlace":"Bethesda, Md.","publisher":"ASPET","dateIssuedDisp":"1909-"}]}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"1 May 2017"}],"language":["eng"],"name":{"displayForm":["Christoph Koepple, Daniel Scherer, Claudia Seyler, Eberhard Scholz, Dierk Thomas, Hugo A. Katus, and Edgar Zitron"]},"person":[{"display":"Köpple, Christoph","given":"Christoph","family":"Köpple","role":"aut"},{"given":"Daniel","display":"Scherer, Daniel","role":"aut","family":"Scherer"},{"given":"Claudia","display":"Seyler, Claudia","family":"Seyler","role":"aut"},{"family":"Scholz","role":"aut","display":"Scholz, Eberhard P.","given":"Eberhard P."},{"given":"Dierk","display":"Thomas, Dierk","family":"Thomas","role":"aut"},{"family":"Katus","role":"aut","given":"Hugo","display":"Katus, Hugo"},{"role":"aut","family":"Zitron","display":"Zitron, Edgar","given":"Edgar"}],"recId":"1582522308","note":["Im Titel ist die Zahl \"2\" nach PIP tiefgestellt","Gesehen am 02.11.2018"]} 
SRT |a KOEPPLECHRDUALMECHAN1201